OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Nuclear Medicine is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	222
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	144
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	134
[ ¹⁷⁷ Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	121
Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies	101
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	101
Localized In Vivo Prodrug Activation Using Radionuclides	91
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	91
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	88
Biochemical Recurrence–Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging	87
Serial [ ¹⁸ F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	79
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	76
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	71
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	69
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	67
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	67
Delta-like Ligand 3–Directed ²²⁵ Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models	66
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	65
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ ¹⁷⁷ Lu]Lu-PSMA Therapy Injections Through Serial	64
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	63
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	63
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	63
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	63
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)	62
Diagnostic Performance of [ ¹⁸ F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study	61

Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies	59
Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	59
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	58
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	57
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	56
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	56
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	55
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	55
Preclinical Evaluation of ⁶⁴ Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging	55
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	55
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	55
Precision Medicine Clinical Trials	55
Translation of Intraoperative Molecular Imaging for Clinical Use	54
The Role of Molecular Imaging in Precision Oncology	54
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	54
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	53
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	53
Funding Reductions Threaten the Future of Medical Innovation	52
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	52
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	51
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	51
Malignancy Detection Rates of [ ⁶⁸ Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer	51
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	50
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	50
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	50